1-4 of 4
Isabelle Fleury
Close
Sort by
Journal Articles

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results

Clinical Trials & Observations
Ulrich Jaeger, Nina Worel, Joseph P. McGuirk, Peter A. Riedell, Isabelle Fleury, Yan Du, Xia Han, David Pearson, Santiago Redondo, Edmund K. Waller
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2283–2286.
https://doi.org/10.1182/bloodadvances.2022007779
Published: 2023
Includes: Supplemental data
Journal Articles

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Ulrich Jaeger, Constantine S. Tam, Peter Borchmann, Joseph P. McGuirk, Marianne Johansen, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Salles, Stephen J. Schuster, Fiona He, Richard T. Maziarz, Sebastian Mayer, Shinichi Makita, Marie J. Kersten, Monalisa Ghosh, Nina Wagner-Johnston, Koji Kato, Paolo Corradini, Hideki Goto, Silvia Colicino, Abhijit Agarwal, Chiara Lobetti-Bodoni, Michael R. Bishop
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4816–4820.
https://doi.org/10.1182/bloodadvances.2021006193
Published: 2022
Includes: Supplemental data
Journal Articles

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Richard T. Maziarz, Edmund K. Waller, Ulrich Jaeger, Isabelle Fleury, Joseph McGuirk, Harald Holte, Samantha Jaglowski, Stephen J. Schuster, Michael R. Bishop, Jason R. Westin, Stephan Mielke, Takanori Teshima, Veronika Bachanova, Stephen R. Foley, Peter Borchmann, Gilles A. Salles, Jie Zhang, Ranjan Tiwari, Lida B. Pacaud, Qiufei Ma, Constantine S. Tam
Journal: Blood Advances
Blood Adv (2020) 4 (4): 629–637.
https://doi.org/10.1182/bloodadvances.2019001026
Published: 2020
Includes: Supplemental data
Journal Articles

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Clinical Trials & Observations
Michael R. Bishop, Richard T. Maziarz, Edmund K. Waller, Ulrich Jäger, Jason R. Westin, Joseph P. McGuirk, Isabelle Fleury, Harald Holte, Peter Borchmann, Christopher del Corral, Ranjan Tiwari, Özlem Anak, Rakesh Awasthi, Lida Pacaud, Vadim V. Romanov, Stephen J. Schuster
Journal: Blood Advances
Blood Adv (2019) 3 (14): 2230–2236.
https://doi.org/10.1182/bloodadvances.2019000151
Published: 2019